Glioblastoma resistance to EGFR antibody-drug conjugate is driven by transcriptional reprogramming and TEK-induced EGFR suppression. - Blomquist, Mylan R.; Noviello, Teresa M. R.; Sereduk, Christopher; Grief, Dustin; Caruso, Francesca P.; Sharma, Ritin; Garcia-Mansfield, Krystine; Pirrotte, Patrick; Kloss, Jean; D'Angelo, Fulvio; Marin, Bianca M.; Porath, Kendra; et al. (Journal of Translational Medicine, 2025)